nach oben

Endocrine

Erschienen in:

19.10.2017 | Meta-Analysis

Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis

verfasst von: Liuting Zeng, Kailin Yang

Erschienen in: Endocrine | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the effectiveness and safety of myoinositol for patients with PCOS.

Methods

In this meta-analysis, data from randomized controlled trials are obtained to assess the effects of myoinositol vs. placebo or western medicine in women with PCOS. The study’s registration number is CRD42017064563. The primary outcomes included total testosterone, estradiol (E2) and the homeostatic model assessment (HOMA) of insulin resistance.

Result

Ten trials involving 573 patients were included. The meta-analysis results show that: compared with the control group, myoinositol may improve HOMA index (WMD −0.65; 95% CI −1.02, −0.28; P = 0. 0005) and increase the E2 level (WMD 16.16; 95% CI 2.01, 30.31; P = 0. 03); while there is no enough strong evidence that the myoinositol has an effect on the total testosterone level (WMD −16.11; 95% CI −46.08, 13.86; P = 0. 29).

Conclusion

Based on current evidence, myoinositol may be recommended for the treatment of PCOS with insulin resistance, as well as for improving symptoms caused by decreased estrogen in PCOS.

Nur mit Berechtigung zugänglich

R. Azziz, K.S. Woods, R. Reyna, T.J. Key, E.S. Knochenhauer, B.O. Yildiz, The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89, 2745–2749 (2004). https://doi.org/10.1210/jc.2003-032046 CrossRefPubMed

Y. Meng, X. Chen, Z. Peng, X. Liu, Y. Sun, S. Dai, Association between high serum homocysteine levels and biochemical characteristics in women with polycystic ovarian syndrome: a systematic review and meta-analysis. PLoS One 11, e0157389 (2016). https://doi.org/10.1371/journal.pone.0157389 CrossRefPubMedPubMedCentral

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group., consensus on diagnostic criteria and long-term healthiest related to polycystic ovary syndrome. Fertil. Steril. 81, 19–25 (2004). https://doi.org/10.1016/j.fertnstert.2003.10.004. Revised 2003

R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Task force on the phenotype of the polycystic ovary syndrome of the androgen excess PCOS society 2009: The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009)CrossRefPubMed

R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Androgen excess society 2006.:, Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91, 4237–4245 (2006)CrossRefPubMed

L.J. Moran, M.L. Misso, R.A. Wild, R.J. Norman, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16, 347–363 (2010)CrossRefPubMed

J. Vague, La différentiation sexuelle. Facteur determinant des formes de l’obesité. Presse Med. 55, 339–340 (1947)PubMed

A.H. Kissebah, N. Vydelingum, R. Murray, D.J. Evans, A.J. Hartz, R.K. Kalkhoff, P.W. Adams, Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 54, 254–260 (1982)CrossRefPubMed

M.A. Kirschner, E. Samojlik, M. Drejka, E. Szmal, G. Schneider, N. Ertel, Androgen-estrogen metabolism in women with upper body versus lower body obesity. J. Clin. Endocrinol. Metab. 70, 473–479 (1990)CrossRefPubMed

10.

C.R. Kahn, J.S. Flier, R.S. Bar, J.A. Archer, P. Gorden, M.M. Martin, J. Roth, The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N. Engl. J. Med. 294, 739–745 (1976)CrossRefPubMed

11.

C. Wu, F. Lin, S. Qiu, Z. Jiang, The characterization of obese polycystic ovary syndrome rat model suitable for exercise intervention. PLoS One 9, e99155 (2014). https://doi.org/10.1371/journal.pone.0099155 CrossRefPubMedPubMedCentral

12.

J.E. Nestler, J.F. Strauss III, Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol. Metab. Clin. N. Am. 20, 807–823 (1991)

13.

J.C. Marshall, A. Dunaif, Should all women with PCOS be treated for insulin resistance? Fertil. Steril. 97, 18–22 (2012)CrossRefPubMedPubMedCentral

14.

J.E. Nestler, D. Stovall, N. Akhter, M.J. Iuorno, D.J. Jakubowicz, Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil. Steril. 77, 209–215 (2002)CrossRefPubMed

15.

V. De Leo, M.C. Musacchio, G. Morgante, P. Piomboni, F. Petraglia, Metformin treatment is effective in obese teenage girls with PCOS. Hum. Reprod. 21, 2252–2256 (2006)CrossRefPubMed

16.

E. Papaleo, V. Unfer, J.P. Baillargeon, F. Fusi, F. Occhi, L. De Santis, Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles: a prospective, controlled, randomized trial. Fertil. Steril. 91, 1750–1754 (2009)CrossRefPubMed

17.

D. Costantino, G. Minozzi, E. Minozzi, C. Guaraldi, Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur. Rev. Med. Pharmacol. Sci. 13, 105–110 (2009)PubMed

18.

G. Donà, C. Sabbadin, C. Fiore, M. Bragadin, F.L. Giorgino, E. Ragazzi, G. Clari, L. Bordin, D. Armanini, Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur. J. Endocrinol. 166, 703–710 (2012). https://doi.org/10.1530/EJE-11-0840 CrossRefPubMed

19.

J.J. Deeks, J.P. Higgins, D.G. Altman, in Special Topics in Statistics, ed. by J.P. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions, Chapter 16 (The Cochrane Collaboration, UK, 2011)

20.

J.J. Deeks, J.P. Higgins, D.G. Altman, in Assessing Risk of Bias in Included Studies, ed. by J.P. Higgins, S. Green Cochrane Handbook or Systematic Reviews of Interventions Version 5.1.0, Chapter 8 (The Cochrane Collaboration, UK, 2011)

21.

J.J. Deeks, J.P. Higgins, D.G. Altman, in Analyzing Data and Undertaking Meta-analyses. ed. by J.P. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions, Chapter 9 (The Cochrane Collaboration, UK, 2011)

22.

E. Benelli, S. Del Ghianda, C. Di Cosmo, M. Tonacchera, A combined therapy with Myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int. J. Endocrinol. 2016, 3204083 (2016). https://doi.org/10.1155/2016/3204083 CrossRefPubMedPubMedCentral

23.

J. Nehra, J. Kaushal, S.R. Singhal, V.S. Gehlaut, A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women. Int. J. Pharm. Sci. Res. 8(4), 1664–1670 (2017). https://doi.org/10.13040/IJPSR.0975-8232

24.

F. Fruzzetti, D. Perini, M. Russo, F. Bucci, A. Gadducci, Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol. Endocrinol. 33, 39–42 (2017)CrossRefPubMed

25.

P.G. Artini, O.M. Di Berardino, F. Papini, A.D. Genazzani, G. Simi, M. Ruggiero, V. Cela, Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol. Endocrinol. 29, 375–379 (2013). https://doi.org/10.3109/09513590.2012.743020 CrossRefPubMed

26.

A.D. Genazzani, C. Lanzoni, F. Ricchieri, V.M. Jasonni, Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol. Endocrinol. 24, 139–144 (2008). https://doi.org/10.1080/09513590801893232 CrossRefPubMed

27.

L. Pkhaladze, L. Barbakadze, N. Kvashilava, Myo-Inositol in the treatment of teenagers affected by PCOS. Int. J. Endocrinol. 2016, 1473612 (2016). https://doi.org/10.1155/2016/1473612 CrossRefPubMedPubMedCentral

28.

S. Gerli, E. Papaleo, A. Ferrari, G.C. Di Renzo, Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur. Rev. Med. Pharmacol. Sci. 11, 347–354 (2007)PubMed

29.

S. Gerli, M. Mignosa, G.C. Di Renzo, Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur. Rev. Med. Pharmacol. Sci. 7, 151–159 (2003)PubMed

30.

Y. Loke, D. Price, A. Herxheimer, in Adverse Effects. ed. by J.P. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions. Chapter 14. (Wiley, Chichester, UK, 2008)

31.

J.P.A. Ioannidis, S.J.W. Evans, P.C. Gøtzsche et al. Better reporting of harms in randomized trials: an extension of the Consort statement. Ann. Intern. Med. 141, 781–788 (2004)CrossRefPubMed

32.

A. Mansour, S. Hosseini, B. Larijani, M.R. Mohajeri-Tehrani, Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome. EXCLI J. 15, 551–564 (2016). https://doi.org/10.17179/excli2016-422. eCollection 2016PubMedPubMedCentral

33.

T.T. Chiu, M.S. Rogers, C. Briton-Jones, C. Haines, Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum. Reprod. 18, 408–416 (2003)CrossRefPubMed

34.

V. Unfer, G. Carlomagno, E. Papaleo, S. Vailati, M. Candiani, J.P. Baillargeon, Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod. Sci. 21, 854–858 (2014)CrossRefPubMed

35.

M.J. Iuorno, D.J. Jakubowicz, J.P. Baillargeon et al. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr. Pract. 8, 417–423 (2002)CrossRefPubMed

36.

J.E. Nestler, D.J. Jakubowicz, P. Reamer, R.D. Gunn, G. Allan, Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N. Engl. J. Med. 340, 1314–1320 (1999)CrossRefPubMed

37.

J.P. Baillargeon, M.J. Iuorno, T. Apridonidze, J.E. Nestler, Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. Metab. Syndr. Relat. Disord. 8, 127–136 (2010). https://doi.org/10.1089/met.2009.0052 CrossRefPubMed

38.

V. Unfer, J.E. Nestler, Z.A. Kamenov, N. Prapas, F. Facchinetti, Effects of inositol(s) in women with PCOS: A systematic review of randomized controlled trials. Int. J. Endocrinol. 2016, 1849162 (2016)CrossRefPubMedPubMedCentral

39.

V. Unfer, G. Carlomagno, G. Dante, F. Facchinetti, Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol. Endocrinol. 28, 509–515 (2012). https://doi.org/10.3109/09513590.2011.650660 CrossRefPubMed

Titel: Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis
verfasst von: Liuting Zeng
Kailin Yang
Publikationsdatum: 19.10.2017
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-017-1442-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis

Abstract

Purpose

Methods

Result

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Result

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Hyperthyroid patients without Graves' orbitopathy are not at increased risk of developing glaucoma: a nationwide Danish register-based case-control study

Oral mucositis induced by treatment with soft gel formulation of levothyroxine

Oxidative stress in adult growth hormone deficiency: different plasma antioxidant patterns in comparison with metabolic syndrome

Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis

Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis

Triiodothyronine differentially modulates the LH and FSH synthesis and secretion in male rats

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin